Risk-Based Monitoring: A Regulatory Perspective on What's Expected from an Independent Assessment of Data
Recorded on March 
25, 2014

This webinar recording provides a regulatory perspective on what is expected from an independent and objective assessment of clinical data.
Discussion points include;

  • What the FDA and EMA are encouraging sponsors to look at as part of their assessment of data quality
  • Identifying the different types of data analysis required to de-risk studies
  • A review of case studies that exemplify a powerful approach to data management

If you have any questions, please don't hesitate to contact us at contact@cluepoints.com